ADMS Adamas Pharmaceuticals Inc.

+0.12  (+1%)
Previous Close 10.99
Open 11
Price To Book 2.66
Market Cap 303697772
Shares 27,335,533
Volume 189,609
Short Ratio
Av. Daily Volume 547,103

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b top-line data released September 7, 2017. Pivotal Phase 3 trial to be initiated 2019.
Partial onset seizures in patents with epilepsy
Phase 3 data due 2H 2019.
GOCOVRI (amantadine)
Multiple sclerosis (MS)
Approved December, 24 2014.
Moderate to severe dementia of the Alzheimer's type.
Approval announced August 24, 2017.
Levodopa-Induced Dyskinesia
Phase 3 open-label data released April 19, 2018.
GOCOVRI (amantadine)
Dyskinesia patients with Parkinson's disease

Latest News

  1. Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
  2. Adamas to Present at Two Upcoming Investor Conferences
  3. Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019
  4. Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
  5. Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?
  6. AptarGroup (ATR) to Report Q4 Earnings: What's in Store?
  7. Should You Be Worried About Insider Transactions At Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)?
  8. Adamas Announces New Employment Inducement Grant
  9. Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings?
  10. Report: Exploring Fundamental Drivers Behind Roku, AECOM, 1-800 FLOWERS.COM, Eldorado Resorts, Haverty Furniture Companies, and Adamas Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
  11. LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index
  12. Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
  13. Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
  14. The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas
  15. Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™
  16. Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy?
  17. Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November
  18. Edited Transcript of ADMS earnings conference call or presentation 1-Nov-18 8:30pm GMT